{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:13:33Z","timestamp":1780758813018,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40119-015-0035-1","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T08:56:22Z","timestamp":1423126582000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case\u2013Control Study"],"prefix":"10.1007","volume":"4","author":[{"given":"Henry W. C.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ling","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes L. F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsin","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"35_CR1","unstructured":"Taiwan Cancer Registry. Available at: http:\/\/www.mc.ntu.edu.tw\/CRS\/main.php?Page=N2 ."},{"issue":"3","key":"35_CR2","first-page":"410","volume":"17","author":"LY Huang","year":"2013","unstructured":"Huang LY, Shau WY, Chen HC, et al. Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study. Eur Rev Med Pharmacol Sci. 2013;17(3):410\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"17","key":"35_CR3","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","volume":"173","author":"CI Li","year":"2013","unstructured":"Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013;173(17):1629\u201337.","journal-title":"JAMA Intern Med"},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","volume":"129","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2011.35.8820","volume":"29","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Cole SW. Expanding our therapeutic options: beta blockers for breast cancer? J Clin Oncol. 2011;29:2612\u20136.","journal-title":"J Clin Oncol"},{"key":"35_CR6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrclinonc.2011.123","volume":"8","author":"DG Powe","year":"2011","unstructured":"Powe DG, Entschladen F. Targeted therapies: using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol. 2011;8:511\u20132.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"35_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65\u201382.","journal-title":"Lancet Oncol"},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2125.2011.03980.x","volume":"72","author":"SM Shah","year":"2011","unstructured":"Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG. Does beta adrenoceptor blocker therapy improve cancer survival? Findings from a population based retrospective cohort study. Br J Clin Pharmacol. 2011;72:157\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"35_CR9","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/ije\/dyt196","volume":"42","author":"CR Cardwell","year":"2013","unstructured":"Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG. Beta-blocker usage and breast cancer survival: a nested case\u2013control study within a UK Clinical Practice Research Datalink cohort. Int J Epidemiol. 2013;42(6):1852\u201361.","journal-title":"Int J Epidemiol"},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","volume":"29","author":"The ARB Trialists Collaboration","year":"2011","unstructured":"The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623\u201335.","journal-title":"J Hypertens"},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","volume":"123","author":"B Pasternak","year":"2011","unstructured":"Pasternak B, Svanstr\u00f6m H, Callr\u00e9us T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729\u201336.","journal-title":"Circulation"},{"key":"35_CR12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"35_CR13","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Application for ATC codes. Available at: http:\/\/www.whocc.no\/atc\/application_for_atc_codes\/ ."},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"issue":"7","key":"35_CR15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.18632\/oncotarget.197","volume":"1","author":"DG Powe","year":"2010","unstructured":"Powe DG, Voss MJ, Z\u00e4nker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628\u201338.","journal-title":"Oncotarget"},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2010.33.4441","volume":"29","author":"A Melhem-Bertrandt","year":"2011","unstructured":"Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645\u201352.","journal-title":"J Clin Oncol"},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1024491219366","volume":"80","author":"TL Drell 4th","year":"2003","unstructured":"Drell TL 4th, Joseph J, Lang K, Manni A. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.20410","volume":"112","author":"K Lang","year":"2004","unstructured":"Lang K, Drell TL 4th, Lindecke A, Niggemann B, Kaltschmidt C. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004;112:231\u20138.","journal-title":"Int J Cancer"},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1006338232150","volume":"60","author":"TA Slotkin","year":"2000","unstructured":"Slotkin TA, Zhang J, Dancel R. Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat. 2000;60:153\u201366.","journal-title":"Breast Cancer Res Treat"},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1038\/sj.onc.1210172","volume":"26","author":"AE Carie","year":"2007","unstructured":"Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1\/Mek-1\/Erk1\/2 pathway. Oncogene. 2007;26:3777\u201388.","journal-title":"Oncogene"},{"key":"35_CR21","first-page":"153","volume":"21","author":"Y Cakir","year":"2002","unstructured":"Cakir Y, Plummer HK 3rd, Tithof PK, Schuller HM. Beta-adrenergic and acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol. 2002;21:153\u20137.","journal-title":"Int J Oncol"},{"key":"35_CR22","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","volume":"70","author":"EK Sloan","year":"2010","unstructured":"Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70:7042\u201352.","journal-title":"Cancer Res"},{"key":"35_CR23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10549-011-1348-y","volume":"130","author":"KS Madden","year":"2011","unstructured":"Madden KS, Szpunar MJ, Brown EB. \u03b2-Adrenergic receptors (\u03b2-AR) regulate VEGF and IL-6 production by divergent pathways in high \u03b2-AR-expressing breast cancer cell lines. Breast Cancer Res Treat. 2011;130:747\u201358.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"35_CR24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3109\/13880209.2014.892513","volume":"52","author":"OD I\u015feri","year":"2014","unstructured":"I\u015feri OD, Sahin FI, Terzi YK, Yurtcu E, Erdem SR, Sarialioglu F. beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol. 2014;52(11):1374\u201381.","journal-title":"Pharm Biol"},{"issue":"2","key":"35_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10552-012-0122-8","volume":"24","author":"BS Saltzman","year":"2013","unstructured":"Saltzman BS, Weiss NS, Sieh W, et al. Use of antihypertensive medications and breast cancer risk. Cancer Causes Control. 2013;24(2):365\u201371.","journal-title":"Cancer Causes Control"},{"issue":"7","key":"35_CR26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/pds.3645","volume":"23","author":"Q Chen","year":"2014","unstructured":"Chen Q, Zhang Q, Zhong F, et al. Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2014;23(7):711\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-015-0035-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T04:59:42Z","timestamp":1498193982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-015-0035-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s40119-015-0035-1","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,6]]}}}